Efficacy and Toxicity Associated with Cancer Drug Approvals in Switzerland: International Implications

The authors comment on a meta-analysis by Rahimzadeh et al. evaluating the clinical benefit and toxicity of cancer drugs approved in Switzerland. Beyond the Swiss context, they explore the global implications of regulatory approvals based on surrogate endpoints and immature survival data, highlighting challenges for evidence standards, patient access, reimbursement decisions, and value-based cancer care.